EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China

Miao Liang, Sisi Liu, Xiaoxu Zhang, Qianna Liu

Frontiers in Pharmacology · 25.06.2026 · 17

DOI: 10.3389/fphar.2026.1845724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 25.06.2026. Verfasst von Miao Liang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study assessed the cost-effectiveness of pyrotinib combined with trastuzumab and docetaxel as a first-line treatment for HER2-positive metastatic breast cancer from the perspective of the Chinese healthcare system.

Methods

A partitioned survival model was constructed to evaluate the cost-effectiveness of this regimen in patients with HER2-positive metastatic breast cancer. The primary outcomes were total costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). The treatment strategy was considered cost-effective when the ICER fell below a predefined willingness-to-pay (WTP) threshold. One-way and probabilistic sensitivity analyses were conducted to address parameter uncertainties. Additional scenario analyses were performed to explore how different assumptions influenced the ICER.

Results

In the base-case analysis, the pyrotinib group incurred total costs of $136,400.69 compared with $83,887.55 in the placebo group. The corresponding effectiveness was 5.20 QALYs versus 3.89 QALYs. The ICER was $40,245.81/QALY, which exceeded the WTP threshold (two times China’s per capita GDP in 2025, $27,906.03/QALY). One-way sensitivity analysis revealed that utility of progression-free survival and the price of pyrotinib were the most influential factors on the ICER. Probabilistic sensitivity analysis indicated that at the WTP threshold of $27,906.03/QALY, pyrotinib had a 6.1% probability of being cost-effective. Scenario analyses confirmed the robustness of the model. Price threshold analysis showed that the price of pyrotinib would need to be reduced by more than 34.45% to bring the ICER below the WTP threshold.

Conclusion

From the Chinese healthcare perspective, pyrotinib combined with trastuzumab and docetaxel may not be cost-effective for HER2-positive metastatic breast cancer under current prices and the WTP threshold. A price reduction would be required to achieve cost-effectiveness.

Schlagwörter

Stichwörter der Autor:innen

cost-effectivenessfirst-line treatmentmetastatic breast cancerpyrotinibtyrosine kinase inhibitor

Autor:innen und Institutionen

  • Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China.

Zitieren

APA

Liang, M., Liu, S., Zhang, X., & Liu, Q. (2026). Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1845724

Vancouver

Liang M, Liu S, Zhang X, Liu Q. Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1845724

BibTeX
@article{Liang2026,
  author = {Liang, Miao and Liu, Sisi and Zhang, Xiaoxu and Liu, Qianna},
  title = {Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1845724}
}
Kostenlos starten →